- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05409326
A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
June 5, 2022 updated by: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
A Phase I Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
A randomized, double-blind, placebo-controlled trial design was used to assess the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics, and immunogenicity of TQH2722 injection in healthy subjects.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yu Cao, Doctor
- Phone Number: 0532-82917310
- Email: caoyu1767@126.com
Study Locations
-
-
Shandong
-
Qingdao, Shandong, China, 266000
- Recruiting
- The Affiliated Hospital of Qingdao University
-
Contact:
- Yu Cao, Doctor
- Phone Number: 0532-82917310
- Email: caoyu1767@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 1 The informed consent was signed before the trial, fully understood the purpose and process of the trial and the possible adverse reactions.
- 2 Aged 18 ~ 60 years old (including the critical value), both male and female;
- 3 ≥ 45 kg for females and ≥ 50 kg for males with a body mass index (BMI) between 19 and 26 kg/m2 inclusive, BMI = weight (kg)/height2 (m2)
- 4 The subject is able to communicate well with the investigator, voluntary and able to understand and follow protocol procedures to complete the study;
- 5 The subject agrees not to have a childbearing plan from the date of signing the informed consent form to 6 months after the last dose, and must use effective non-drug contraception with a partner of childbearing potential;
- 6 Normal physical examination, vital signs or abnormal physical examination, vital signs without clinical significance
Exclusion Criteria:
- 1 Females who are pregnant, lactating or have unprotected sex within two weeks prior to screening;
- 2 Past medical history or current cardiac, endocrine, metabolic, renal, hepatic, gastrointestinal, skin, infection, hematological, neurological or psychiatric diseases/abnormalities, or related chronic diseases, or acute diseases, and the investigator evaluated that the subject was not suitable for the trial;
- 3 People who have abnormal and clinically significant results in vital signs, physical examination, laboratory tests, eye examination, 12-lead ECG and X-ray during screening period;
- 4 Subjects Positive for Any of Hepatitis B Virus Surface Antigen (HBsAg), Hepatitis C Virus Antibody (Anti-HCV), Human Immunodeficiency Virus Antibody (Anti-HIV), and Treponema Pallidum Antibody (Anti-TP);
- 5 Clinically significant respiratory infection requiring antibiotic or antiviral therapy within 7 days prior to randomization;
- 6 People who received surgical operation within 4 weeks prior to screening, or planned to receive surgical operation during the study period;
- 7 People who participated in other clinical trials and took the study drug within 3 months before screening;
- 8 Received immunoglobulins or blood products within 30 days prior to randomization;
- 9 Blood loss or blood donation of more than 400 mL within 2 months prior to randomization;
- 10 People who have potential difficulty in blood collection, or have a history of halo needles or blood sickness;
- 11 A history of allergic reactions to another therapeutic monoclonal antibody or biologic agent therapy, or any clear history of drug or food allergies, particularly those with allergies to similar components to the drug in this trial;
- 12 People who have received or are planning to receive live-reduced or active vaccines during the 30 days prior to randomization and the entire study period (including the follow-up period);
- 13 Smoking more than 5 cigarettes per day or using equivalent amounts of nicotine or nicotine-containing products during the 6 months prior to randomization and the entire study period (including the follow-up period);
- 14 People who had long-standing alcohol abuse or alcohol consumption of more than 14 units (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) of alcohol per week during the 3 months prior to screening and the entire study period (including the follow-up period), or those who tested positive for alcohol breath;
- 15 People with a history of substance abuse or positive urine drug screening;
- 16 Received any marketed or research biologics within 4 months or 5 half-lives (whichever is longer) prior to randomization;
- 17 Taking any prescription, over-the-counter and herbal medicines within 4 weeks prior to randomization, with the exception of vitamin products;
- 18 Use of any systemic cytotoxicity or systemic immunosuppressants within 6 months prior to randomization or during the study period, or any local cytotoxin or local immunosuppressive drug within 30 days or 5 half-life periods (whichever is longer) prior to randomization or during the study period;
19 Parasitic infection is associated and is excluded if any of the following are met:
- During the screening period, the stool routinely checks positive for eggs;
- History of parasitic infection within 6 months prior to the screening period;
- Have traveled or planned to travel to endemic parasitic infection areas (including but not limited to Southeast and South-West Asia, South America and Africa) within 6 months prior to screening visits;
- 20 Any situation in which the investigator believes that this poses a safety risk to the subject in the trial or may interfere with the conduct of the study, or that the investigator believes that the subject may not be able to complete the study or may not be able to comply with the requirements of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TQH2722 injection
Participants will receive single dose of TQH2722 injection under fasted condition (Single Ascending Dose(SAD) Cohorts 50mg, 150mg, 300mg, 600mg, 1200mg) on Day 1, or will receive multiple doses of TQH2722 injection once every 14 days under fasted condition (Multiple-Dose Administration (MAD) Cohort 150mg, 600mg) on Day 1-43.
|
TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway.
Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
|
Placebo Comparator: Placebo to match TQH2722
Participants will receive single dose of matching placebo under fasted condition (Single Ascending Dose(SAD) Cohorts 50mg, 150mg, 300mg, 600mg, 1200mg) on Day 1, or will receive multiple doses of matching placebo once every 14 days under fasted condition (Multiple-Dose Administration (MAD) Cohort 150mg, 600mg) on Day 1-43.
|
TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway.
Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events (AE)
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Incidence and severity of adverse events (AE) .
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Serious adverse events (SAE)
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Incidence and severity of Serious adverse events (SAE).
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Blood biochemistry
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Abnormal indicators of blood biochemistry.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Coagulation function
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Abnormal indicators of coagulation function.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Blood routine
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Abnormal indicators of blood routine.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Urinalysis
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Abnormal indicators of urinalysis.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Blood pressure
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Abnormal values of blood pressure
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Pulse
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Abnormal values of blood pulse.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Body temperature
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Abnormal values of blood body temperature.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Skin
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Examination of the skin.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Mucous membranes
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Examination of the mucous membranes.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Lymph nodes
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Examination of the lymph nodes.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Head
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Examination of the head.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Neck
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Examination of the neck.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Chest
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Examination of the chest.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Abdomen
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Examination of the abdomen.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Spine
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Examination of the spine.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Limbs
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Examination of the limbs.
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
12-lead electrocardiogram
Time Frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Abnormal values of 12-lead electrocardiogram
|
From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Concentration(Cmax)
Time Frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Maximum Concentration
|
SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Minimum Concentration(Cmax)
Time Frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Minimum Concentration
|
SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Time to maximum concentration(Tmax)
Time Frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Time to maximum concentration following drug administration
|
SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Area under the drug-time curve(AUC)
Time Frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Area under the drug-time curve
|
SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Apparent terminal elimination half-life(t1/2)
Time Frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Apparent terminal elimination half-life following drug administration
|
SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Apparent volume of distribution(Vd/F)
Time Frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Apparent volume of distribution
|
SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.
|
Clearance rate(CL/F)
Time Frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose
|
Clearance rate
|
SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose
|
Immunoglobulin E(IgE)
Time Frame: SAD:Before administration,168,336,504,672,1008,1344 hours after administration. MAD:Before every administration,336,672,1344 hours after the last administration.
|
Percentage of changes in serum IgE
|
SAD:Before administration,168,336,504,672,1008,1344 hours after administration. MAD:Before every administration,336,672,1344 hours after the last administration.
|
Thymus activation regulates chemokines(TARC)
Time Frame: SAD:Before administration,168,336,504,672,1008,1344 hours after administration. MAD:Before every administration,336,672,1344 hours after the last administration.
|
Percentage of changes in serum TARC
|
SAD:Before administration,168,336,504,672,1008,1344 hours after administration. MAD:Before every administration,336,672,1344 hours after the last administration.
|
Anti-drug antibody (ADA)
Time Frame: SAD:Before administration,336,1344 hours after administration. MAD:Before the first administration;Before the third administration;336,1344 hours after the last administration.
|
Incidence and titer of anti-drug antibody
|
SAD:Before administration,336,1344 hours after administration. MAD:Before the first administration;Before the third administration;336,1344 hours after the last administration.
|
Neutralizing Antibody(Nab)
Time Frame: SAD:Before administration,336,1344 hours after administration. MAD:Before the first administration;Before the third administration;336,1344 hours after the last administration.
|
Incidence of Neutralizing Antibody
|
SAD:Before administration,336,1344 hours after administration. MAD:Before the first administration;Before the third administration;336,1344 hours after the last administration.
|
Injection site response
Time Frame: Before administration,0.5,1,3,6 hours after administration.
|
Injection site response assessment
|
Before administration,0.5,1,3,6 hours after administration.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 1, 2022
Primary Completion (Anticipated)
June 1, 2023
Study Completion (Anticipated)
August 1, 2023
Study Registration Dates
First Submitted
May 24, 2022
First Submitted That Met QC Criteria
June 5, 2022
First Posted (Actual)
June 8, 2022
Study Record Updates
Last Update Posted (Actual)
June 8, 2022
Last Update Submitted That Met QC Criteria
June 5, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQH2722-I-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on TQH2722 injection
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAtopic DermatitisChina
-
Chia Tai Tianqing Pharmaceutical Group Nanjing...Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated